Amneal Crexont 1 of 1 4C CREXONT® is a registered trademark of Amneal Pharmaceuticals LLC. © 2025 Amneal Pharmaceuticals LLC. Distributed by Amneal Specialty, a division of Amneal Pharmaceuticals LLC. All rights reserved. PP-ADP-CREX-US-0031 08/2025 Next level levodopa Levodopa plasma levels that last. Discover what’s inside CREXONT at CREXONTHCP.COM References: 1. Hauser RA, Espay AJ, Ellenbogen AL, et al. IPX203 vs immediate-release carbidopa-levodopa for the treatment of motor fluctuations in Parkinson disease: the RISE-PD Randomized Clinical Trial. JAMA Neurol. 2023;80(10):1062-1069. 2. LeWitt P, Ellenbogen A, Burdick D, et al. Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation. Clin Park Relat Disord. 2023;8:100197. 3. Modi NB, Mittur A, Rubens R, Khanna S, Gupta S. Single-dose pharmacokinetics and pharmacodynamics of IPX203 in patients with advanced Parkinson disease: a comparison with immediate-release carbidopa-levodopa and with extended-release carbidopa-levodopa capsules. Clin Neuropharmacol. 2019;42(1):4-8. While immediate-release granules dissolve rapidly, the extended-release pellets inside CREXONT® (carbidopa and levodopa) are built to last. Each ER pellet is designed with a novel mucoadhesive polymer that helps the levodopa reach the optimal area of absorption, where it can release slowly, making CREXONT the oral CD/LD therapy with the longest-lasting LD plasma levels.1-3*† *Based on the time that LD plasma levels were maintained above 50% of Cmax. †Exact site and duration of absorption are unknown. CD/LD=carbidopa/levodopa; Cmax=maximum observed plasma concentration; ER=extended-release; LD=levodopa.
View this content as a flipbook by clicking here.